, CHAPTER LIST
Chapter 1: Drugs and Drug Targets
Chapter 2: Protein Structure and Function
Chapter 3: Enzymes: Structure and Function
Chapter 4: Receptors: Structure and Function
Chapter 5: Receptors and Signal Transduction
Chapter 6: Nucleic Acids: Structure and Function
Chapter 7: Enzymes as Drug Targets
Chapter 8: Receptors as Drug Targets
Chapter 9: Nucleic Acids as Drug Targets
Chapter 10: Miscellaneous Drug Targets
Chapter 11: Pharmacokinetics and Related Topics
Case Study 1: Statins
Chapter 12: Drug Discovery: Finding a Lead
Chapter 13: Drug Design: Optimizing Target Interactions
Chapter 14: Drug Design: Optimizing Access to the Target
Chapter 15: Getting the Drug to Market
Case Study 2: The Design of ACE Inhibitors
Case Study 3: Artemisinin and Related Antimalarial Drugs
Case Study 4: The Design of Oxamni
Case Study 5: Fosfidomycin as an Antimalarial Agent
Chapter 16: Combinatorial and Parallel Synthesis
Chapter 17: In Silico Drug Design
Chapter 18: Quantitative Structure-Activity Relationships
Case Study 6: De Novo Design of a Thymidylate Synthase Inhibitor
Chapter 19: Antibacterial Agents
Chapter 20: Antiviral Agents
Chapter 21: Anticancer Agents
Chapter 22: Protein Kinase Inhibitors as Anticancer Agents
Chapter 23: Antibodies and Other Biologics
Chapter 24: Cholinergics, Anticholinergics, and Anticholinestarases
Chapter 25: Drugs Acting on the Adrenergic Nervous System
Chapter 26: The Opioid Analgesics
Chapter 27: Anti-Ulcer Agents
Chapter 28: Cardiovascular Drugs
Case Study 7: Steroidal Anti-Inflammatory Agents
Case Study 8: Design of a Novel Antidepressant
Case Study 9: The Design and Development Of Aliskiren
Case Study 10: Factor Xa Inhibitors
Case Study 11: Reversible Inhibitors of HCV NS-34A Protease
,Chapter 1: Drugs and Drug Targets
Question 1 [MCQ – Scenario | Application]
A medicinal chemist is attempting to design a drug that mimics the action of an
endogenous neurotransmitter at a receptor but wishes to reduce the risk of maximal
receptor overstimulation. The team therefore selects a compound that binds to the
same site as the endogenous ligand, activates the receptor, but produces a lower
maximal response even when all receptors are occupied. Which term best describes this
candidate?
A. Competitive antagonist
B. Inverse agonist
C. Partial agonist
D. Irreversible antagonist
Answer: C
Rationale: A partial agonist binds to the same receptor site as the endogenous agonist
and activates the receptor, but it has lower intrinsic efficacy. As a result, even at full
receptor occupancy, it cannot produce the same maximal response as a full agonist. This
concept is important in medicinal chemistry because partial agonists can preserve some
physiological signaling while limiting overstimulation, making them useful where a
buffered pharmacological effect is desirable. Their behavior reflects both binding affinity
and efficacy, illustrating that receptor occupancy alone does not determine the
magnitude of biological response.
Question 2 [MCQ – Scenario | Application]
A lead compound contains a permanently charged ammonium group that forms a
strong ionic interaction with an anionic amino acid residue in its target binding site.
During optimization, the chemist removes this charged group and replaces it with a
neutral hydrophobic substituent. Biological testing shows a major loss in potency. Which
explanation best accounts for this observation?
,A. The neutral substituent increased van der Waals interactions sufficiently to replace the
ionic bond
B. Removal of the charged group likely disrupted a major binding interaction that
contributed substantially to affinity
C. The modification converted the compound from reversible to irreversible binding
D. The hydrophobic substituent necessarily converted the drug into an inverse agonist
Answer: B
Rationale: Ionic interactions are among the strongest non-covalent forces involved in
drug-target recognition and often make major contributions to binding affinity,
especially when a charged functional group is precisely positioned to interact with an
oppositely charged residue in the target site. Replacing a permanently charged
ammonium group with a neutral hydrophobic substituent can remove a key anchor
point from the pharmacophore and markedly weaken binding. In medicinal chemistry,
this illustrates that not all interactions are interchangeable: hydrophobic contacts may
improve fit in nonpolar regions, but they do not simply compensate for the loss of a
specific, directional electrostatic interaction that was crucial for target recognition.
Question 3 [MCQ – Scenario | Analysis]
A drug candidate is highly effective against a pathogenic enzyme, but subsequent
testing shows covalent reaction with several human proteins containing reactive
nucleophilic residues, producing toxicity. Which feature of the candidate most likely
explains both its efficacy and its safety problem?
A. It relies exclusively on weak van der Waals interactions
B. It binds reversibly through hydrophobic interactions only
C. It contains a reactive group capable of irreversible covalent bonding
D. It was derived from an endogenous ligand
Answer: C
Rationale: Irreversible inhibitors commonly contain reactive functional groups that form
covalent bonds with nucleophilic residues in their biological targets. This can generate
prolonged inhibition and high apparent potency because the drug-target complex is not
readily reversed by dilution or competition. However, the same chemical reactivity can
,create toxicity if the reactive group is insufficiently selective and modifies off-target
proteins. This scenario highlights a central medicinal chemistry principle: covalent
bonding can be a powerful design strategy, but it demands precise control of reactivity,
target recognition, and selectivity to avoid widespread protein modification and adverse
effects.
Question 4 [MCQ – Recall | Knowledge]
Which of the following best represents the principal pharmacological meaning of the
term “drug”?
A. Any substance whose sale is regulated by law
B. A compound that affects biological systems by interacting with a molecular target
C. Any natural product used in traditional medicine
D. A chemical that must cure disease to be clinically relevant
Answer: B
Rationale: In pharmacological and medicinal chemistry contexts, a drug is understood
primarily as a chemical agent that produces a biological effect through interaction with
components of living systems, usually by binding to a molecular target such as a
receptor, enzyme, nucleic acid, ion channel, or membrane-associated structure. This
definition emphasizes mechanism and biological action rather than legal classification.
Legal definitions vary by jurisdiction and often include substances of abuse or controlled
compounds irrespective of therapeutic value, whereas pharmacological definitions focus
on the capacity of a molecule to alter physiological or pathological processes through
molecular recognition.
Question 5 [MCQ – Recall | Knowledge]
Which option correctly lists the four broad classes of drug targets emphasized in
introductory medicinal chemistry?
A. Receptors, enzymes, nucleic acids, miscellaneous targets
B. Receptors, antibodies, carbohydrates, lipoproteins
C. Enzymes, vitamins, hormones, transport vesicles
D. Receptors, DNA, plasma proteins, metabolites
,Answer: A
Rationale: A foundational classification in medicinal chemistry organizes drug targets
into four broad categories: receptors, enzymes, nucleic acids, and miscellaneous targets.
This scheme is useful because it frames the major types of molecular recognition events
relevant to drug action. Receptors mediate signaling; enzymes catalyze biochemical
reactions and can be inhibited or modulated; nucleic acids can be targeted to affect
gene expression or replication; and miscellaneous targets include membranes, ion
channels, transporters, structural proteins, and other biomolecules that do not fit neatly
into the first three categories. This classification helps students understand how
chemical structure is tailored to biological function.
Question 6 [MCQ – Recall | Knowledge]
What is a pharmacophore?
A. The metabolic pathway by which a drug is inactivated
B. The toxicophoric region responsible for adverse effects
C. The ensemble of steric and electronic features required for optimal interaction with a
target
D. The legal name assigned during regulatory approval
Answer: C
Rationale: A pharmacophore is the set of essential steric and electronic features that a
molecule must possess to interact optimally with a biological target and produce a
desired biological response. It is not a whole molecule but an abstract map of critical
interaction elements, such as hydrogen bond donors or acceptors, ionic centers,
hydrophobic groups, and aromatic features, arranged in three-dimensional space.
Pharmacophore thinking is central to lead discovery and optimization because it allows
chemists to identify the minimum structural requirements for activity, compare
structurally diverse active compounds, and design new analogues that preserve the key
interaction pattern.
Question 7 [MCQ – Recall | Knowledge]
Which statement correctly distinguishes drug names?
,A. The generic name is the full structural formula of the compound
B. The chemical name is assigned for marketing purposes
C. The brand name is the non-proprietary standard name used across manufacturers
D. The generic name is the approved non-proprietary name for the active substance
Answer: D
Rationale: The generic name is the approved non-proprietary name assigned to the
active pharmaceutical substance and is intended for general scientific, medical, and
prescribing use. It differs from the brand name, which is proprietary and chosen by a
manufacturer for marketing a specific product formulation. It also differs from the
chemical name, which systematically describes the molecular structure according to
chemical nomenclature conventions. Understanding this distinction is important in
medicinal chemistry because a single active drug substance may be encountered under
multiple naming systems, and structural interpretation depends on recognizing whether
a name is chemical, generic, or commercial.
Question 8 [MCQ – Comprehension | Understanding]
Why are endogenous ligands often valuable starting points in drug design?
A. They are always orally active and metabolically stable
B. They have already evolved to interact with biological targets and therefore reveal key
recognition features
C. They are legally simpler to develop than synthetic compounds
D. They invariably show perfect selectivity for one receptor subtype
Answer: B
Rationale: Endogenous ligands are useful templates because they have evolved to bind
productively to biological macromolecules and therefore embody many of the
recognition features required for target interaction. Their structures can reveal the
spatial arrangement of pharmacophoric elements needed for binding and activation or
inhibition. However, endogenous ligands are often unsuitable as drugs in their native
form because they may be rapidly metabolized, poorly selective, too polar, or unable to
reach the desired site of action. Medicinal chemists therefore use them as mechanistic
,starting points, modifying their structures to improve stability, selectivity, and
pharmacokinetic behavior while preserving essential target-binding features.
Question 9 [MCQ – Comprehension | Understanding]
Which statement best explains the difference between an agonist and an inverse
agonist?
A. An agonist binds irreversibly, whereas an inverse agonist binds reversibly
B. An agonist increases receptor activity above basal levels, whereas an inverse agonist
reduces constitutive receptor activity below basal levels
C. An agonist binds to enzymes, whereas an inverse agonist binds to receptors
D. An agonist always has higher affinity than an inverse agonist
Answer: B
Rationale: An agonist stabilizes the active state of a receptor and increases signaling
above the basal level, whereas an inverse agonist preferentially stabilizes an inactive
receptor state and reduces constitutive activity below the baseline level seen in the
absence of ligand. This distinction is only meaningful for receptors that possess
measurable constitutive activity. The concept is important because it separates efficacy
from affinity: both agonists and inverse agonists may bind the same receptor, but they
bias receptor conformational equilibria in opposite directions. This mechanistic idea is
fundamental to modern receptor pharmacology and drug design.
Question 10 [MCQ – Comprehension | Understanding]
Why is reversible drug-target binding often advantageous in therapeutics?
A. It guarantees absence of toxicity
B. It allows target inhibition to diminish as drug concentration falls, helping control
duration of action
C. It always produces greater potency than irreversible binding
D. It prevents all off-target interactions
Answer: B
Rationale: Reversible binding is advantageous because the extent of target occupancy
,and pharmacological effect generally tracks drug concentration. As the drug is
metabolized or excreted, the equilibrium shifts and the target is progressively freed,
allowing control over the intensity and duration of action. This can improve dosing
flexibility and reduce the risk of prolonged adverse effects. In medicinal chemistry,
reversible interactions are often preferred unless there is a specific rationale for covalent
inhibition, because they offer a balance between efficacy and reversibility while avoiding
the sustained consequences of permanent target modification.
Question 11 [MCQ – Comprehension | Understanding]
Which statement best captures the relationship between selectivity and specificity in
drug action?
A. A drug that is selective must interact with only one biological target under all
conditions
B. Selectivity is usually a matter of degree and depends on relative affinity, dose, and
target distribution
C. Specificity means the drug has no pharmacological effect
D. Selectivity is determined only by whether the drug is synthetic or natural
Answer: B
Rationale: In medicinal chemistry, selectivity is rarely absolute; it is typically a relative
property arising from preferential interaction with one target over others. The degree of
selectivity depends not only on molecular affinity but also on concentration, route of
administration, exposure, and the distribution of targets in the body. A compound may
appear selective at low concentrations yet engage additional targets at higher levels.
This is why medicinal chemists usually speak of improved selectivity rather than
complete specificity. The concept is crucial because therapeutic utility often depends on
maximizing the difference between desired and undesired target interactions.
Question 12 [MCQ – Application | Problem Solving]
A highly active compound is unsuitable for oral administration because it is too polar to
cross biological membranes efficiently. The chemist masks a carboxylic acid as an ester,
and the modified compound is later hydrolyzed in vivo to release the active acid. This
strategy is best described as:
, A. Bioisosteric replacement
B. Prodrug design
C. Inverse agonist design
D. Affinity labeling
Answer: B
Rationale: Prodrug design involves temporary chemical modification of an active drug to
improve properties such as membrane permeability, absorption, solubility, chemical
stability, or tissue targeting. Masking a carboxylic acid as an ester is a classic medicinal
chemistry strategy because the ester is less ionized and often more lipophilic, enhancing
passive membrane transport. Once absorbed, esterases can hydrolyze the prodrug to
regenerate the pharmacologically active acid. This approach demonstrates that
optimization of a therapeutic agent may involve not only target affinity but also rational
control of physicochemical and biopharmaceutical properties needed for successful
delivery.
Question 13 [MCQ – Application | Problem Solving]
A medicinal chemistry team compares two analogues with similar target affinity.
Compound X interacts with several related receptor subtypes and produces dose-
limiting adverse effects. Compound Y retains activity at the intended receptor while
showing much weaker binding to the others. Which property has most clearly improved
in Compound Y?
A. Therapeutic index through enhanced selectivity
B. Chemical nomenclature
C. Legal classification
D. Irreversible target binding
Answer: A
Rationale: When a compound retains intended target activity while markedly reducing
interaction with related off-target receptors, its selectivity has improved. This can
directly contribute to a better therapeutic index because therapeutic effects may be
achieved at doses that do not substantially engage the off-target systems responsible
for adverse effects. The therapeutic index reflects the relationship between toxic and
Chapter 1: Drugs and Drug Targets
Chapter 2: Protein Structure and Function
Chapter 3: Enzymes: Structure and Function
Chapter 4: Receptors: Structure and Function
Chapter 5: Receptors and Signal Transduction
Chapter 6: Nucleic Acids: Structure and Function
Chapter 7: Enzymes as Drug Targets
Chapter 8: Receptors as Drug Targets
Chapter 9: Nucleic Acids as Drug Targets
Chapter 10: Miscellaneous Drug Targets
Chapter 11: Pharmacokinetics and Related Topics
Case Study 1: Statins
Chapter 12: Drug Discovery: Finding a Lead
Chapter 13: Drug Design: Optimizing Target Interactions
Chapter 14: Drug Design: Optimizing Access to the Target
Chapter 15: Getting the Drug to Market
Case Study 2: The Design of ACE Inhibitors
Case Study 3: Artemisinin and Related Antimalarial Drugs
Case Study 4: The Design of Oxamni
Case Study 5: Fosfidomycin as an Antimalarial Agent
Chapter 16: Combinatorial and Parallel Synthesis
Chapter 17: In Silico Drug Design
Chapter 18: Quantitative Structure-Activity Relationships
Case Study 6: De Novo Design of a Thymidylate Synthase Inhibitor
Chapter 19: Antibacterial Agents
Chapter 20: Antiviral Agents
Chapter 21: Anticancer Agents
Chapter 22: Protein Kinase Inhibitors as Anticancer Agents
Chapter 23: Antibodies and Other Biologics
Chapter 24: Cholinergics, Anticholinergics, and Anticholinestarases
Chapter 25: Drugs Acting on the Adrenergic Nervous System
Chapter 26: The Opioid Analgesics
Chapter 27: Anti-Ulcer Agents
Chapter 28: Cardiovascular Drugs
Case Study 7: Steroidal Anti-Inflammatory Agents
Case Study 8: Design of a Novel Antidepressant
Case Study 9: The Design and Development Of Aliskiren
Case Study 10: Factor Xa Inhibitors
Case Study 11: Reversible Inhibitors of HCV NS-34A Protease
,Chapter 1: Drugs and Drug Targets
Question 1 [MCQ – Scenario | Application]
A medicinal chemist is attempting to design a drug that mimics the action of an
endogenous neurotransmitter at a receptor but wishes to reduce the risk of maximal
receptor overstimulation. The team therefore selects a compound that binds to the
same site as the endogenous ligand, activates the receptor, but produces a lower
maximal response even when all receptors are occupied. Which term best describes this
candidate?
A. Competitive antagonist
B. Inverse agonist
C. Partial agonist
D. Irreversible antagonist
Answer: C
Rationale: A partial agonist binds to the same receptor site as the endogenous agonist
and activates the receptor, but it has lower intrinsic efficacy. As a result, even at full
receptor occupancy, it cannot produce the same maximal response as a full agonist. This
concept is important in medicinal chemistry because partial agonists can preserve some
physiological signaling while limiting overstimulation, making them useful where a
buffered pharmacological effect is desirable. Their behavior reflects both binding affinity
and efficacy, illustrating that receptor occupancy alone does not determine the
magnitude of biological response.
Question 2 [MCQ – Scenario | Application]
A lead compound contains a permanently charged ammonium group that forms a
strong ionic interaction with an anionic amino acid residue in its target binding site.
During optimization, the chemist removes this charged group and replaces it with a
neutral hydrophobic substituent. Biological testing shows a major loss in potency. Which
explanation best accounts for this observation?
,A. The neutral substituent increased van der Waals interactions sufficiently to replace the
ionic bond
B. Removal of the charged group likely disrupted a major binding interaction that
contributed substantially to affinity
C. The modification converted the compound from reversible to irreversible binding
D. The hydrophobic substituent necessarily converted the drug into an inverse agonist
Answer: B
Rationale: Ionic interactions are among the strongest non-covalent forces involved in
drug-target recognition and often make major contributions to binding affinity,
especially when a charged functional group is precisely positioned to interact with an
oppositely charged residue in the target site. Replacing a permanently charged
ammonium group with a neutral hydrophobic substituent can remove a key anchor
point from the pharmacophore and markedly weaken binding. In medicinal chemistry,
this illustrates that not all interactions are interchangeable: hydrophobic contacts may
improve fit in nonpolar regions, but they do not simply compensate for the loss of a
specific, directional electrostatic interaction that was crucial for target recognition.
Question 3 [MCQ – Scenario | Analysis]
A drug candidate is highly effective against a pathogenic enzyme, but subsequent
testing shows covalent reaction with several human proteins containing reactive
nucleophilic residues, producing toxicity. Which feature of the candidate most likely
explains both its efficacy and its safety problem?
A. It relies exclusively on weak van der Waals interactions
B. It binds reversibly through hydrophobic interactions only
C. It contains a reactive group capable of irreversible covalent bonding
D. It was derived from an endogenous ligand
Answer: C
Rationale: Irreversible inhibitors commonly contain reactive functional groups that form
covalent bonds with nucleophilic residues in their biological targets. This can generate
prolonged inhibition and high apparent potency because the drug-target complex is not
readily reversed by dilution or competition. However, the same chemical reactivity can
,create toxicity if the reactive group is insufficiently selective and modifies off-target
proteins. This scenario highlights a central medicinal chemistry principle: covalent
bonding can be a powerful design strategy, but it demands precise control of reactivity,
target recognition, and selectivity to avoid widespread protein modification and adverse
effects.
Question 4 [MCQ – Recall | Knowledge]
Which of the following best represents the principal pharmacological meaning of the
term “drug”?
A. Any substance whose sale is regulated by law
B. A compound that affects biological systems by interacting with a molecular target
C. Any natural product used in traditional medicine
D. A chemical that must cure disease to be clinically relevant
Answer: B
Rationale: In pharmacological and medicinal chemistry contexts, a drug is understood
primarily as a chemical agent that produces a biological effect through interaction with
components of living systems, usually by binding to a molecular target such as a
receptor, enzyme, nucleic acid, ion channel, or membrane-associated structure. This
definition emphasizes mechanism and biological action rather than legal classification.
Legal definitions vary by jurisdiction and often include substances of abuse or controlled
compounds irrespective of therapeutic value, whereas pharmacological definitions focus
on the capacity of a molecule to alter physiological or pathological processes through
molecular recognition.
Question 5 [MCQ – Recall | Knowledge]
Which option correctly lists the four broad classes of drug targets emphasized in
introductory medicinal chemistry?
A. Receptors, enzymes, nucleic acids, miscellaneous targets
B. Receptors, antibodies, carbohydrates, lipoproteins
C. Enzymes, vitamins, hormones, transport vesicles
D. Receptors, DNA, plasma proteins, metabolites
,Answer: A
Rationale: A foundational classification in medicinal chemistry organizes drug targets
into four broad categories: receptors, enzymes, nucleic acids, and miscellaneous targets.
This scheme is useful because it frames the major types of molecular recognition events
relevant to drug action. Receptors mediate signaling; enzymes catalyze biochemical
reactions and can be inhibited or modulated; nucleic acids can be targeted to affect
gene expression or replication; and miscellaneous targets include membranes, ion
channels, transporters, structural proteins, and other biomolecules that do not fit neatly
into the first three categories. This classification helps students understand how
chemical structure is tailored to biological function.
Question 6 [MCQ – Recall | Knowledge]
What is a pharmacophore?
A. The metabolic pathway by which a drug is inactivated
B. The toxicophoric region responsible for adverse effects
C. The ensemble of steric and electronic features required for optimal interaction with a
target
D. The legal name assigned during regulatory approval
Answer: C
Rationale: A pharmacophore is the set of essential steric and electronic features that a
molecule must possess to interact optimally with a biological target and produce a
desired biological response. It is not a whole molecule but an abstract map of critical
interaction elements, such as hydrogen bond donors or acceptors, ionic centers,
hydrophobic groups, and aromatic features, arranged in three-dimensional space.
Pharmacophore thinking is central to lead discovery and optimization because it allows
chemists to identify the minimum structural requirements for activity, compare
structurally diverse active compounds, and design new analogues that preserve the key
interaction pattern.
Question 7 [MCQ – Recall | Knowledge]
Which statement correctly distinguishes drug names?
,A. The generic name is the full structural formula of the compound
B. The chemical name is assigned for marketing purposes
C. The brand name is the non-proprietary standard name used across manufacturers
D. The generic name is the approved non-proprietary name for the active substance
Answer: D
Rationale: The generic name is the approved non-proprietary name assigned to the
active pharmaceutical substance and is intended for general scientific, medical, and
prescribing use. It differs from the brand name, which is proprietary and chosen by a
manufacturer for marketing a specific product formulation. It also differs from the
chemical name, which systematically describes the molecular structure according to
chemical nomenclature conventions. Understanding this distinction is important in
medicinal chemistry because a single active drug substance may be encountered under
multiple naming systems, and structural interpretation depends on recognizing whether
a name is chemical, generic, or commercial.
Question 8 [MCQ – Comprehension | Understanding]
Why are endogenous ligands often valuable starting points in drug design?
A. They are always orally active and metabolically stable
B. They have already evolved to interact with biological targets and therefore reveal key
recognition features
C. They are legally simpler to develop than synthetic compounds
D. They invariably show perfect selectivity for one receptor subtype
Answer: B
Rationale: Endogenous ligands are useful templates because they have evolved to bind
productively to biological macromolecules and therefore embody many of the
recognition features required for target interaction. Their structures can reveal the
spatial arrangement of pharmacophoric elements needed for binding and activation or
inhibition. However, endogenous ligands are often unsuitable as drugs in their native
form because they may be rapidly metabolized, poorly selective, too polar, or unable to
reach the desired site of action. Medicinal chemists therefore use them as mechanistic
,starting points, modifying their structures to improve stability, selectivity, and
pharmacokinetic behavior while preserving essential target-binding features.
Question 9 [MCQ – Comprehension | Understanding]
Which statement best explains the difference between an agonist and an inverse
agonist?
A. An agonist binds irreversibly, whereas an inverse agonist binds reversibly
B. An agonist increases receptor activity above basal levels, whereas an inverse agonist
reduces constitutive receptor activity below basal levels
C. An agonist binds to enzymes, whereas an inverse agonist binds to receptors
D. An agonist always has higher affinity than an inverse agonist
Answer: B
Rationale: An agonist stabilizes the active state of a receptor and increases signaling
above the basal level, whereas an inverse agonist preferentially stabilizes an inactive
receptor state and reduces constitutive activity below the baseline level seen in the
absence of ligand. This distinction is only meaningful for receptors that possess
measurable constitutive activity. The concept is important because it separates efficacy
from affinity: both agonists and inverse agonists may bind the same receptor, but they
bias receptor conformational equilibria in opposite directions. This mechanistic idea is
fundamental to modern receptor pharmacology and drug design.
Question 10 [MCQ – Comprehension | Understanding]
Why is reversible drug-target binding often advantageous in therapeutics?
A. It guarantees absence of toxicity
B. It allows target inhibition to diminish as drug concentration falls, helping control
duration of action
C. It always produces greater potency than irreversible binding
D. It prevents all off-target interactions
Answer: B
Rationale: Reversible binding is advantageous because the extent of target occupancy
,and pharmacological effect generally tracks drug concentration. As the drug is
metabolized or excreted, the equilibrium shifts and the target is progressively freed,
allowing control over the intensity and duration of action. This can improve dosing
flexibility and reduce the risk of prolonged adverse effects. In medicinal chemistry,
reversible interactions are often preferred unless there is a specific rationale for covalent
inhibition, because they offer a balance between efficacy and reversibility while avoiding
the sustained consequences of permanent target modification.
Question 11 [MCQ – Comprehension | Understanding]
Which statement best captures the relationship between selectivity and specificity in
drug action?
A. A drug that is selective must interact with only one biological target under all
conditions
B. Selectivity is usually a matter of degree and depends on relative affinity, dose, and
target distribution
C. Specificity means the drug has no pharmacological effect
D. Selectivity is determined only by whether the drug is synthetic or natural
Answer: B
Rationale: In medicinal chemistry, selectivity is rarely absolute; it is typically a relative
property arising from preferential interaction with one target over others. The degree of
selectivity depends not only on molecular affinity but also on concentration, route of
administration, exposure, and the distribution of targets in the body. A compound may
appear selective at low concentrations yet engage additional targets at higher levels.
This is why medicinal chemists usually speak of improved selectivity rather than
complete specificity. The concept is crucial because therapeutic utility often depends on
maximizing the difference between desired and undesired target interactions.
Question 12 [MCQ – Application | Problem Solving]
A highly active compound is unsuitable for oral administration because it is too polar to
cross biological membranes efficiently. The chemist masks a carboxylic acid as an ester,
and the modified compound is later hydrolyzed in vivo to release the active acid. This
strategy is best described as:
, A. Bioisosteric replacement
B. Prodrug design
C. Inverse agonist design
D. Affinity labeling
Answer: B
Rationale: Prodrug design involves temporary chemical modification of an active drug to
improve properties such as membrane permeability, absorption, solubility, chemical
stability, or tissue targeting. Masking a carboxylic acid as an ester is a classic medicinal
chemistry strategy because the ester is less ionized and often more lipophilic, enhancing
passive membrane transport. Once absorbed, esterases can hydrolyze the prodrug to
regenerate the pharmacologically active acid. This approach demonstrates that
optimization of a therapeutic agent may involve not only target affinity but also rational
control of physicochemical and biopharmaceutical properties needed for successful
delivery.
Question 13 [MCQ – Application | Problem Solving]
A medicinal chemistry team compares two analogues with similar target affinity.
Compound X interacts with several related receptor subtypes and produces dose-
limiting adverse effects. Compound Y retains activity at the intended receptor while
showing much weaker binding to the others. Which property has most clearly improved
in Compound Y?
A. Therapeutic index through enhanced selectivity
B. Chemical nomenclature
C. Legal classification
D. Irreversible target binding
Answer: A
Rationale: When a compound retains intended target activity while markedly reducing
interaction with related off-target receptors, its selectivity has improved. This can
directly contribute to a better therapeutic index because therapeutic effects may be
achieved at doses that do not substantially engage the off-target systems responsible
for adverse effects. The therapeutic index reflects the relationship between toxic and
